Clinical trials: Nocturia
Sleep Fragmentation, Poor Quality Sleep
Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production
Nocturia is prevalent in older adults and it vastly reduces quality of life. Yet its treatment remains inadequate because its causes are not well understood, especially nocturnal polyuria or increased urine production at night.
- Conditions
- Sleep Fragmentation, Poor Quality Sleep, Nocturia, Nocturnal Enuresis
- Trial name
- NCT03883724
- Testing
- Brief behavioral treatment of insomnia (BBTI), Information-only control (IC)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Overactive Bladder, Incontinence
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
This purpose of this study is to understand the types of bacteria that are in the bladder and vagina in patients with overactive bladder (OAB) symptoms and understand if the types of bacteria change when with the use of estrogen…
- Conditions
- Overactive Bladder, Incontinence, Nocturia
- Trial name
- FUM (NCT02835846)
- Testing
- Estrogen Cream
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Loyola University
Nocturia
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
The purpose of this trial was to confirm/establish long-term safety and efficacy of desmopressin orally disintegrating tablets at dose levels of 50 μg and 75 μg and to further evaluate the safety of an efficacious higher dose…
- Trial name
- NCT01262456
- Testing
- Desmopressin
- Where
- 56 sites in United States, Canada
- Volunteers
- 395 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia, Hypertension
Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
In this study the investigators target three common and comorbid illnesses among older adults namely nocturia or waking at night to void, poor sleep and hypertension.
- Conditions
- Nocturia, Hypertension, Sleep Disturbance
- Trial name
- SHyN (NCT05419830)
- Testing
- BBTI, PM antihypertensive dosing or Chronotherapy, AM antihypertensive dosing
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Urinary Incontinence
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets.
- Trial name
- NCT00323635
- Testing
- tolterodine
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Nocturia
Treatment of Patients With Nocturia (Non-PK Study)
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937378
- Testing
- SER120
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Overactive Bladder, Parkinson Disease
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
The impact of urinary symptoms in Parkinson disease (PD) extends beyond worsened well-being. Urinary symptoms common in PD, especially incontinence and nocturia, are major risk factors for falls likely due to the combination of…
- Trial name
- BOSS PD (NCT03149809)
- Testing
- solifenacin, Pelvic floor muscle exercise-based behavioral therapy
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- VA Office of Research and Development
Nocturia
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
The purpose of this study is to investigate the efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00477490
- Testing
- desmopressin acetate
- Where
- 80 sites in United States, Canada
- Volunteers
- 799 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia, Daytime Sleepiness
Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as a means of improving residual daytime sleepiness in patients with treated nocturia.
- Trial name
- NCT02151253
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Duke University
Interstitial Cystitis, Chronic Interstitial Cystitis
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to gather information from the investigation of a non-pharmacological (non-drug) treatment known as low frequency pulsed electromagnetic field (PEMF).
- Conditions
- Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT04540887
- Testing
- Pulsed Electromagnetic Field (PEMF) Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Nocturia
Treatment of Patients With Nocturia
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937859
- Testing
- SER120
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with…
- Trial name
- COMFORT (NCT01223937)
- Testing
- Desmopressin
- Where
- 45 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of…
- Trial name
- NCT01729819
- Testing
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00615836
- Testing
- Desmopressin Melt
- Where
- 73 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Insomnia Disorder, Nocturia
A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia
A study to find out if daridorexant is safe and efficacious in patients with insomnia and comorbid nocturia
- Trial name
- NCT05597020
- Testing
- Daridorexant
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.